{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:06:45Z","timestamp":1789031205717,"version":"build-2803163510"},"reference-count":10,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.tips.2026.08.001","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:10:27Z","timestamp":1787055027000},"page":"949-951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trojan mast cells: repurposing allergy for targeted oncolytic delivery"],"prefix":"10.1016","volume":"47","author":[{"given":"Mengqin","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2026.08.001_bb0005","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tips.2026.08.001_bb0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","article-title":"Clinical trial links oncolytic immunoactivation to survival in glioblastoma","volume":"623","author":"Ling","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.tips.2026.08.001_bb0015","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2026.08.001_bb0020","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/s41551-021-00815-9","article-title":"Genetically engineered and enucleated human mesenchymal stromal cells for the targeted delivery of therapeutics to diseased tissue","volume":"6","author":"Wang","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.tips.2026.08.001_bb0025","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/s41551-021-00712-1","article-title":"Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets","volume":"5","author":"Hu","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.tips.2026.08.001_bb0030","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","article-title":"Natural killer cell therapies","volume":"626","author":"Vivier","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.tips.2026.08.001_bb0035","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.cell.2021.02.048","article-title":"Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis","volume":"184","author":"Kaczanowska","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.tips.2026.08.001_bb0040","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/s41587-023-02118-7","article-title":"An oncolytic virus\u2013T cell chimera for cancer immunotherapy","volume":"42","author":"Chen","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tips.2026.08.001_bb0045","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.cell.2025.11.015","article-title":"Sensitized mast cells for targeted drug delivery and augmented cancer immunotherapy","volume":"189","author":"Xu","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.tips.2026.08.001_bb0050","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nri3690","article-title":"Mast cell secretory granules: armed for battle","volume":"14","author":"Wernersson","year":"2014","journal-title":"Nat. Rev. Immunol."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614726001987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614726001987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:10:39Z","timestamp":1789027839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614726001987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0165614726001987"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2026.08.001","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trojan mast cells: repurposing allergy for targeted oncolytic delivery","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2026.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}